AR081401A1 - Compuestos de espiro isoxazolina como antagonistas de sstr5 - Google Patents

Compuestos de espiro isoxazolina como antagonistas de sstr5

Info

Publication number
AR081401A1
AR081401A1 ARP110101689A ARP110101689A AR081401A1 AR 081401 A1 AR081401 A1 AR 081401A1 AR P110101689 A ARP110101689 A AR P110101689A AR P110101689 A ARP110101689 A AR P110101689A AR 081401 A1 AR081401 A1 AR 081401A1
Authority
AR
Argentina
Prior art keywords
heterocycle
substituted
halogen
alkyl
cycloalkyl
Prior art date
Application number
ARP110101689A
Other languages
English (en)
Spanish (es)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AR081401A1 publication Critical patent/AR081401A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ARP110101689A 2010-05-18 2011-05-17 Compuestos de espiro isoxazolina como antagonistas de sstr5 AR081401A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34568310P 2010-05-18 2010-05-18

Publications (1)

Publication Number Publication Date
AR081401A1 true AR081401A1 (es) 2012-08-29

Family

ID=44991994

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101689A AR081401A1 (es) 2010-05-18 2011-05-17 Compuestos de espiro isoxazolina como antagonistas de sstr5

Country Status (8)

Country Link
US (1) US20130040978A1 (cg-RX-API-DMAC7.html)
EP (1) EP2571356A4 (cg-RX-API-DMAC7.html)
JP (1) JP2013529210A (cg-RX-API-DMAC7.html)
AR (1) AR081401A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011256444B2 (cg-RX-API-DMAC7.html)
CA (1) CA2799414A1 (cg-RX-API-DMAC7.html)
TW (1) TW201200524A (cg-RX-API-DMAC7.html)
WO (1) WO2011146324A1 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8742110B2 (en) 2010-08-18 2014-06-03 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
US20150166528A1 (en) 2012-06-14 2015-06-18 Basf Se Pesticidal methods using substituted 3-pyridyl thiazole compounds and derivatives for combating animal pests
FR3000064A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes
JP6247697B2 (ja) * 2013-03-14 2017-12-13 武田薬品工業株式会社 スピロアゼチジンイソキサゾール誘導体及びそのｓｓｔｒ５アンタゴニストとしての使用
EP3083642B1 (en) * 2013-12-17 2018-09-05 Merck Sharp & Dohme Corp. Fused bicyclic isoxazolines as inhibitors of cholesterol ester transfer protein
CN104945416B (zh) * 2014-03-24 2017-11-17 中国科学院上海药物研究所 一类螺异噁唑啉衍生物、其制备方法及医药用途
WO2015146561A1 (ja) * 2014-03-26 2015-10-01 住友精化株式会社 臭化芳香族エステル化合物の製造方法
EP3174537B1 (en) * 2014-07-29 2021-06-23 Merck Sharp & Dohme Corp. Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
TW201712012A (zh) 2015-06-16 2017-04-01 美國禮來大藥廠 ２－側氧基－１，３，８－三氮雜螺［４．５］癸－３－基羧酸衍生物
CN110088089B (zh) 2016-10-25 2023-08-29 勃林格殷格翰国际有限公司 苄基氨基吡啶基环丙烷甲酸、药物组合物及其用途
US10793530B2 (en) 2017-01-26 2020-10-06 Boehringer Ingelheim International Gmbh Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
JP7023969B2 (ja) 2017-01-26 2022-02-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
EP3596062A4 (en) 2017-03-16 2020-08-26 Crinetics Pharmaceuticals, Inc. SOMATOSTATIN MODULATORS AND THEIR USES
EP3752498B1 (en) 2018-02-12 2023-06-28 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
SI3853218T1 (sl) 2018-09-18 2025-06-30 Crinetics Pharmaceuticals, Inc. Modulatorji somatostatina in njihova uporaba
TWI841768B (zh) 2019-08-14 2024-05-11 美商克林提克斯醫藥股份有限公司 非肽生長抑制素(somatostatin)5型受體激動劑及其用途
IL291985A (en) 2019-10-07 2022-06-01 Kallyope Inc Gpr119 agonists
EP4073075A4 (en) * 2019-12-03 2023-12-27 Kallyope, Inc. Sstr5 antagonists
PH12022552277A1 (en) 2020-02-28 2024-03-04 Kallyope Inc Gpr40 agonists
UY39222A (es) 2020-05-19 2021-11-30 Kallyope Inc Activadores de la ampk
EP4172162A4 (en) 2020-06-26 2024-08-07 Kallyope, Inc. AMPK ACTIVATORS
WO2022177974A1 (en) 2021-02-17 2022-08-25 Crinetics Pharmaceuticals, Inc. Crystalline forms of a somatostatin modulator
CN115215787A (zh) * 2021-04-19 2022-10-21 中国科学院上海药物研究所 生长抑素受体5拮抗剂及其用途
CN116354961B (zh) * 2021-12-27 2025-07-25 中国科学院上海药物研究所 生长抑素受体5拮抗剂及其药物组合物及用途
CN114230552B (zh) * 2021-12-29 2023-11-03 江苏广域化学有限公司 三氟甲氧基二苯并噻吩、其制备方法及相关中间体的制备方法
WO2024129614A1 (en) 2022-12-13 2024-06-20 Crinetics Pharmaceuticals, Inc. Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof
CN115819186B (zh) * 2023-02-14 2023-05-16 广东银珠医药科技有限公司 一种3,5-二氯苯甲醇的新型制备方法
CN120752056A (zh) 2023-03-27 2025-10-03 思可海雅药品株式会社 生长激素分泌促进剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939418A (en) * 1995-12-21 1999-08-17 The Dupont Merck Pharmaceutical Company Isoxazoline, isothiazoline and pyrazoline factor Xa inhibitors
AU6780398A (en) * 1997-03-28 1998-10-22 Du Pont Merck Pharmaceutical Company, The Heterocyclic integrin inhibitor prodrugs
DE102005044813A1 (de) * 2005-05-19 2007-10-04 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
BRPI0615449A2 (pt) * 2005-09-02 2011-05-17 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método de tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de sst do subtipo 5 e uso desses compostos
BRPI0617673C1 (pt) * 2005-10-19 2012-05-22 Ranbaxy Lab Ltd composições de inibidores de fosfodiesterase do tipo iv

Also Published As

Publication number Publication date
EP2571356A1 (en) 2013-03-27
US20130040978A1 (en) 2013-02-14
JP2013529210A (ja) 2013-07-18
CA2799414A1 (en) 2011-11-24
TW201200524A (en) 2012-01-01
WO2011146324A1 (en) 2011-11-24
AU2011256444A1 (en) 2012-10-18
EP2571356A4 (en) 2013-11-20
AU2011256444B2 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
AR081401A1 (es) Compuestos de espiro isoxazolina como antagonistas de sstr5
CL2014003277A1 (es) Compuestos derivados heterociclicos sustituidos por carboxamida o sulfonamida, como moduladores para el receptor nuclear huerfano rorgama; composicion farmaceutica que los comprende, util para el tratamiento de artritis reumatoide, lupus eritematoso, psoriasis, esclerosis multiple, diabetes tipo 1, colitis ulcerosa, enfermedad pulmonar obstructiva cronica, entre otras.
CL2014000288A1 (es) Compuestos tipo anilina; proceso para preparar dicho compuesto; uso del compuesto para controlar plagas de invertebrados; forma cristalina de un compuesto.
AR069862A1 (es) Inhibidores de pi3 quinasa
PE20141996A1 (es) Compuestos con actividad nematicida
ES2869172T3 (es) Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro
CO6852096A2 (es) Métodos plaguicidasque utilizan compuestos de 3-piridil tiazol sustituidos y derivados para combatir las plagas de animales i
AR095823A1 (es) Compuesto de ciclopropanamina y uso del mismo
DOP2012000263A (es) Compuestos quimicos
AR088668A1 (es) Moleculas pequeñas que contienen boro
PE20141691A1 (es) Compuestos con actividad nematicida
AR098912A1 (es) Inhibidores de syk
CR20140195A (es) Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas
BR112014004235A2 (pt) derivados de isoxazolina como compostos inseticidas
AR091285A1 (es) Inhibidores de bromodominio y sus usos
AR105668A1 (es) 2-amino-3-fluoro-3-(fluorometil)-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
CL2013003602A1 (es) Compuestos derivados de benzoimidazol (indol) de analogos de espirocarbamato o sus sales como antagonistas de trpv4; composicion farmaceutica que los comprende, util para el tratamiento de aterosclerosis, trastornos relacionados con edema intestinal, trastornos pulmonares, enfermedad cardiovascular, disfuncion renal, osteoartritis, entre otras.
PE20161368A1 (es) Inhibidores de diacilglicerol aciltranferasa 2
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
PE20142282A1 (es) Nuevos derivados de aril-quinolina
AR102217A1 (es) Derivados de benzotiofenilo sustituidos como agonistas de gpr40 para el tratamiento de la diabetes tipo ii
AR080969A1 (es) Compuesto biciclico
AR111199A1 (es) Compuesto aromático agonista de gpr40
AR097866A1 (es) Derivados de 4-azaindol
PE20190414A1 (es) Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal